



Reduced-dose radiation in human papillomavirus-associated oropharyngeal carcinoma can improve outcome: a systematic review and meta-analysis

Meng-Qi Yang^{1#}, Yun-Chang Liu^{2#}, Jiang-Dong Sui^{1,3#}, Fu Jin^{1,3}, Dan Li³, Lu Zhang³, Nuo-Han Wang³, Yue Xie¹, Ying Wang^{1,2,3}, Yong-Zhong Wu^{1,2,3}

¹Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, China; ²College of Bioengineering, Chongqing University, Chongqing, China; ³College of Medicine, Chongqing University, Chongqing, China

Contributions: (I) Conception and design: MQ Yang, YC Liu, JD Sui; (II) Administrative support: Y Wang, YZ Wu, Y Xie; (III) Provision of study materials or patients: F Jin, D Li, L Zhang, NH Wang; (IV) Collection and assembly of data: MQ Yang, YC Liu; (V) Data analysis and interpretation: MQ Yang, YC Liu, JD Sui; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Yue Xie, MD; Ying Wang, PhD; Yong-Zhong Wu, PhD. Chongqing University Cancer Hospital, No. 181 Hanyu Road, Shapingba District, Chongqing 400030, China. Email: 344899525@qq.com; yingwang197011@163.com; yongzhongwu123@163.com.

Background: Despite its effectiveness, the standard course of chemoradiation for the treatment of human papillomavirus (HPV)-related oropharyngeal carcinoma (OPC) results in considerable treatment-related adverse effects. Studies proved that HPV-positive OPC is very sensitive to radiotherapy. Using de-escalation therapy as a new strategy is critical to maintaining positive outcomes while alleviating side effects. However, some studies hold that reduced dose causes insufficient effect on tumor killing. We conducted this systematic review and meta-analysis of survival and adverse reactions in patients with HPV-related OPC by retrospective analysis and evaluated the therapeutic effect of reducing the radiation dose.

Methods: Data were double-selected and extracted by searching seven electronic databases, Original studies in all language treated HPV-associated OPC with reduced-dose and standard-dose therapies were included. Overall survival (OS), progression-free survival (PFS), and incidence rates of adverse events were obtained by pooling analyses. Statistical analyses were performed using RStudio Version 1.1.383 (RStudio, Boston, MA, USA) via the Meta-Analysis R Package (metafor). Heterogeneity was evaluated using the I^2 statistic and the Cochran Q test. We used Stata (version 15.0) for forest graph.

Results: Thirteen studies were included in this meta-analysis, involving a dose range of 66–70 Gy for the standard treatment regimen and <66 Gy for the reduced-dose group. There was no significant difference in the age of the patients in the standard and the reduced treatment groups (60.9 ± 5.9 vs. 58.6 ± 2.4 years). Nine studies were included as standard cohort and thirteen studies were enrolled as reduced-dose cohort. The 2- and 3-year overall survival rates in the reduced-dose group (95.66% and 91.51%, respectively) were superior to those in the standard-dose group (88.36% and 87.46%, respectively). There was no significant difference in PFS between the two groups. A systematic review of articles on dose reduction and the standard dose was also conducted. The most common complication in reduced-dose radiation was oral mucositis (36.4%), followed by decreased white blood cell (WBC) count (30.5%) and dry mouth (29.1%).

Conclusions: Reducing the radiation dose in patients with HPV-related OPC substantially alleviates the treatment toxicities and optimizes the quality of life of patients while at the same time maintaining favorable oncologic outcomes.

Keywords: Human papillomavirus (HPV)-related; reduced dose; oropharyngeal cancer; radiotherapy

Submitted Nov 17, 2022. Accepted for publication Dec 19, 2022.

doi: 10.21037/atm-22-5935

View this article at: <https://dx.doi.org/10.21037/atm-22-5935>

1 Introduction

2 Head and neck squamous cell carcinoma (HNSCC) is
3 one of the most common malignant tumors worldwide,
4 with about 750,000 new cases and 360,000 cancer-related
5 deaths in 2020 (1). About 60% of HNSCC cases are
6 locally advanced at the time of diagnosis, and the current
7 standard of treatment is radical concurrent chemoradiation
8 or surgery followed by radiation therapy (2). HNSCC
9 includes cancers of the oral cavity, larynx, hypopharynx,
10 and oropharynx (3), while oropharyngeal carcinoma (OPC)
11 involves carcinomas of the tonsils, base of the tongue, soft
12 palate, and uvula. Although the incidence of head and neck
13 cancer has steadily declined over the past few decades as
14 smoking rates have decreased, the incidence of OPC is
15 generally ascending, mainly due to the increase in human
16 papillomavirus (HPV) infection (4). According to previous
17 studies, HPV-related OPC reached 71% and 51.8% in the
18 United States and the United Kingdom, respectively (5-8).
19 Of these, 85–96% of cases are caused by HPV-16 infection.
20 The latest version of the American Joint Committee on
21 Cancer (AJCC) staging system classifies OPC into HPV-
22 positive (HPV+) and HPV-negative (HPV-) based on their
23

different molecular profiles, tumor characteristics, and 24
outcomes (9). A series of preclinical and clinical studies 25
(10,11) have shown that HPV-associated OPC has increased 26
sensitivity to chemoradiotherapy and is associated with a 27
more favorable prognosis (12). 28

29 Despite its effectiveness, the standard 7-week course
of chemoradiotherapy for HPV-related OPC results 30
in considerable treatment-related adverse effects (13), 31
Radiotherapy can cause acute and late complications. Acute 32
complications consist of dermatitis, mucositis, dysphagia, 33
odynophagia, alopecia and so on. Besides, skin changes, 34
xerostomia, dental caries, trismus, lymphedema, and 35
swallowing dysfunction are common in late complications. 36
Reports showed the interaction between the dose of 37
radiotherapy and adverse reactions. Such as, the dose of 38
middle and superior constrictors exceeded 55 Gy lead 39
to long-term swallowing dysfunction, and radiotherapy 40
combined with high-dose cisplatin can cause severe late 41
toxicity (14). Acute and late complications give rise to 42
discontinuation of treatment and decreased the quality of 43
life. After radiation and high-dose cisplatin, patients with 44
HPV-related OPC have significantly longer survival periods 45
than those without (10), but the quality of life of these 46
patients is significantly impaired for decades. De-escalation 47
treatment for HPV-related OPC aims to minimize the 48
post-treatment side effects while simultaneously prolonging 49
survival. Research on de-escalation strategies involves 50
the following: (I) reducing the radiotherapy dose while 51
increasing induction chemotherapy; (II) reducing the 52
radiotherapy dose by increasing transoral robotic surgery; 53
(III) reducing radiotherapy dose and cisplatin; and (IV) 54
replacing cisplatin with cetuximab (15-19). 55

56 Several clinical trials (16,18,19) have shown that the
radiation dose to gross disease can be safely reduced 57
in HPV-positive OPC patients, typically by 10–16 Gy. 58
However, some scholars hold that reduced-dose in HPV- 59
positive patients would only quickly reduce the tumor 60
volume in a short period of time, but it may cause risks 61
to patients in the long term (20). Few studies conducted 62
systematic reviews and meta-analyses to determine whether 63
lowering the radiation dose affects survival and adverse 64
effects in HPV-related OPC patients. Therefore, in our 65
study, we compared the radiation effect of reduced-dose 66

Highlight box

Key findings

- Reducing the radiation dose in patients with HPV-related OPC substantially mitigates treatment toxicities and optimizes the quality of life of patients while at the same time maintaining favorable oncologic outcomes.

What is known and what is new?

- It is known that patients with HPV-related OPC have significantly longer survival periods than those without.
- This analysis revealed that de-escalation treatment for HPV-related OPC minimizes the post-treatment side effects while simultaneously prolonging survival.

What are the implications, and what should change now?

- Our findings imply that lower doses of radiotherapy can achieve similar therapeutic effects and involve fewer adverse reactions.
- Numerous clinical studies are still underway, so we hope that there will be more data to support this discovery and guide future clinical treatment.

67 and standard-dose treatments on prognosis in HPV-
68 related OPC and conducted a systematic review of the
69 adverse effects following dose reduction. We present the
70 following article in accordance with the MOOSE reporting
71 checklist (available at [https://atm.amegroups.com/article/
72 view/10.21037/atm-22-5935/rc](https://atm.amegroups.com/article/view/10.21037/atm-22-5935/rc)).
73

74 **Methods**

75 *Search strategy*

76 A systematic search was conducted for relevant studies
77 published before September 15, 2021, in the PubMed,
78 Embase, Cochrane, ProQuest, Scopus, ScienceDirect, and
79 the Web of Science electronic databases. The subject terms
80 “oropharynx cancer/ carcinoma” or “OPC” were combined
81 with the following specific terms: “human papillomavirus
82 viruses”, “human papillomavirus”, “HPV”, “P16”, and
83 “radiotherapy”.
84
85

86 *Selection criteria*

87 The inclusion criteria were as follows: (I) Articles involving
88 patients diagnosed with oral cancer; (II) studies with more
89 than 20 patients; (III) research involving patients confirmed
90 as HPV+ or P16+ by immunohistochemistry or other
91 evidence; and (IV) studies involving a therapeutic plan
92 that applies dose reduction; (V) Studies of all language.
93 (The enrolled articles were all in English after screening.);
94 (VI) case reports, comments, editorials, and reviews were
95 excluded.
96

97 Articles were independently screened and then selected
98 by two reviewers. In cases of studies overlapping, only the
99 study with the most comprehensive data was selected when
100 the patient populations were from the same institution,
101 based on the consensus between the two reviewers. If
102 differences in opinion between the two reviewers needed to
103 be resolved, a third reviewer was consulted.
104

105 *Data extraction*

106 Relevant characteristics were extracted from each study,
107 including the first author’s name, publication year, country,
108 study design, sample size, study participant age, study
109 participant sex (the percentage of males), stage, smoking
110 status (the percentage of fewer than 20 packs per year), and
111 follow-up period (*Table 1*). Two reviewers independently
112 extracted the information from the included studies. We
113
114

then extracted the radiation and chemotherapy schemes for
reduced dose (RD) and standard dose (SD), respectively
(*Tables 2,3*). According to the clinical outcomes, the 2- and
3-year overall survival (OS) and progression-free survival
(PFS) rates were also obtained. Several studies reported
Kaplan-Meier survival curves rather than survival outcomes
directly, but the survival outcomes could also be extracted
from these survival curves. During this analysis, we did not
attempt to obtain missing data by contacting the studies’
authors. Also, given the lack of reports on adverse reactions
(AEs) in the standard dose group, only the AEs of the
reduced-dose group were counted, as shown in *Table 4*.

Statistical analysis

Both random and fixed effects models were used to pool
analysis of the OS and PFS for SD and RD. Given that
few articles contained both the standard and reduced-dose
treatments, a meta-analysis of the standard and reduced-
dose treatment subsets was conducted separately. The I^2
statistic was used to measure the degree of heterogeneity
caused by variability in the true effect size. Statistical
analysis was performed using the SPSS (version 15.0) and
R language (version 1.6.3, <http://www.Rproject.org>). Meta-
analysis was conducted by using the R package meta (34).
Forest plots were created by the metaprop function of meta
package, and funnel plots were constructed by the funnel
function to estimate the publication bias. Egger’s test was
performed to estimate the indexes of funnel asymmetry. If
the funnel plot was not significantly asymmetrical, trim-
and fill- analyses were performed.

Results

Literature search and study characteristics

The search process is displayed in *Figure 1*. A total of
4,634 articles published before September 15th, 2021
were identified through the initial database search. We
then excluded 869 overlapping studies, and a further 3,720
articles were excluded based on their improper titles and
abstracts. The full texts of the remaining 45 studies were
assessed, and studies with insufficient data or inappropriate
populations, treatments, and sizes were excluded. Finally,
13 studies were included in the meta-analysis, among which
nine were SD studies and 13 were RD studies (*Table 1*).
The selected articles were single-arm observational articles,
controlled trials, or randomized studies.

Table 1 Characteristics of the included studies

Author	Year	Country	Sample size	Median/mean age of included patients (years)	Male (%)	AJCC stage	Smoking status	Follow-up period (months)
Chen (21)	2017	USA	44	60	NA	III–IV	30 (68.0%) never smoked, and 14 (32.0%) had ≤ 20 pack year	30
Marur (22)	2017	USA	51	58	96.0	III–IV	23 (45.0%) never smoked, and 14 (28.0%) had ≤ 20 pack year	35.4
Yom (23)	2021	USA	157	NA	84.7	NA	112 (71.3%) never smoked, and 45 (38.7%) had ≤ 20 pack year	30
Misiukiewicz (24)	2019	USA	20	56.5	95.0	NA	12 (60%) never smoked, and eight (40%) had ≤ 20 pack year	56
Fietkau (25)	2020	Germany	32	NA	NA	III–IVB	NA	44
Moore (26)	2021	USA	194	58	90.2	II–IV	148 (76.3%) never smoked, and 46 (23.7%) had ≤ 20 pack year	49
Chera (27)	2018	USA	44	61	88.6	NA	36 (81.8%) never smoked, and eight (18.2%) had ≤ 20 pack year	36
Echevarria (28)	2019	USA	484	NA	NA	NA	NA	36
Huang (29)	2020	Canada	315	NA	77.8	NA	101 (32.1%) never smoked, and 214 (67.9%) had ≤ 20 pack year	57.6
Gabani (30)	2019	USA	759	58.5	86.0	NA	NA	30.5
Tam (31)	2020	USA	2173	57	85.5	III–IV	NA	33.8
Chin (32)	2016	USA	175	56.2	92.0	III–IV	59 (33.7%) never smoked, and 116 (66.3%) had ≤ 20 pack year	70.8
White (33)	2020	USA	192	NA	NA	NA	NA	60

NA, not available; AJCC, American Joint Committee on Cancer.

163 The sample sizes of the SD studies ranged from eight to
 164 2,049 (Table 2) and those of the RD studies ranged from 12
 165 to 157 (Table 3). The ages of patients treated with SD were
 166 similar to those who received RD (60.9 \pm 5.9 vs. 58.6 \pm 2.4 years).
 167 There were no significant gender differences observed
 168 between the SD and RD groups (percentage of males,
 169 85.8% vs. 84.8%). Also, the mean follow-up times of the
 170 RD and SD studies were compared. Regarding the SD
 171 treatment regimen, the total dose ranged from 66 to 70 Gy,
 172 while that of the RD regimen was <66 Gy.

173

174

OS comparison between SD and RD in HPV-related OPC patients

175

176

177

178

179

180

We conducted a meta-analysis of the SD and RD treatment groups. The results showed that the 2-year overall survival (2y-OS) and 3-year overall survival (3y-OS) were better in the RD group compared to the SD group ($P < 0.05$, Figure 2).

Four SD trials showed that the 2y-OS was 88.36% (86.23–90.49%), and eight SD trials indicated that the 3y-OS was 87.46% (86.91–88.01%). Meanwhile, seven RD trials showed that the 2-year OS was 95.66% (94.74–96.59%), and 11 RD trials showed that the 3-year OS was 91.51% (90.61–92.41%). There was no significant difference in PFS between RD and SD; the 2y-PFS and 3y-PFS rates were 89.29% vs. 90.7% and 87.07% vs. 89.71%, respectively ($P \geq 0.05$, Figure 3).

181

182

183

184

185

186

187

188

189

190

191

Analysis of the adverse reactions in RD patients

We performed a systematic review and analysis of the articles on RD treatment (Table 4). Among the four studies analyzed, Misiukiewicz *et al.* showed that the incidence rates of oral mucositis, neutropenia, and urinary retention were all 8.3%. According to Marur *et al.*, rash was the most common adverse reaction (54.9%) followed by neutrophil

191

192

193

194

195

196

197

198

Table 2 Characteristics of the included standard dose studies

Author	Sample size	Median/mean age (years)	Male (%)	T stage	N stage	RT dose	Concurrent therapy	Clinical outcomes
Misiukiewicz (24)	8	55	NA	T1-T2-4; T3-2; T4-2	N0-1; N1-N2-3; N2c-N3-4	70 Gy/35 fx to involved areas and 56 Gy/35 fx to elective neck; cSD and cPD received the latter regimen	2 of 8 patients received concurrent carboplatin	2-y OS: 83.3%; 3-y OS: 83.3%
Fietkau (25)	NA	NA	NA	NA	NA	The prescribed radiation doses included 70.6 Gy to the gross primary tumor volume, 58 Gy to involved nodal levels, and 49.6 Gy to neck regions at low-risk	Fluorouracil 600 mg/m ² ; cisplatin 20 mg/m ² , days 1-5 and 29-33	2-y OS: 89.2%; 3-y OS: 83.5%
Moore (26)	115	55	90	T1-42; T2-58; T3-11; T4-4	N0-6; N1-91; N2-18	RT (60 Gy IMRT) or chemoradiotherapy (cisplatin with 60 Gy IMRT)	RT (60 Gy IMRT) or chemoradiotherapy (cisplatin with 60 Gy IMRT)	3-y OS: 93.0%
Echevarria (28)	338	NA	NA	NA	NA	≥69.3 Gy given over a median of 35 fractions in a median of 200 cGy per fraction	NA	3-y OS: 91.1%
Huang (29)	254	66.8	82	T1-T2-162; T3-T4-92	N0-N2a-93; N2b-104; N2c-47; N3-10	Moderately accelerated radiotherapy alone, 70 Gy in 35 fractions over 6 weeks	NA	3-y OS: 82.0%
Gabani (30)	655	59	86.3	T1-129; T2-199; T3-129; T4-139	N0-79; N1-90; N2a-59; N2b-216; N2c-125; N3-39; NA-47	66 Gy in 25 fractions over 5 weeks	NA	3-y OS: 79.3%
Tam (31)	2049	NA	85.5	T1-418; T2-1033; T3-549; NA-49	N0-187; N1-314; N2-139; N2a-204; N2b-911; N2c-285; NA-9	≥66 Gy in 25 fractions over 5 weeks	NA	3-y OS: 88.5%
Chin (32)	109	56.2	93.6	T1-34; T2-41; T3-15; T4a-18; T4b-0	N0-3; N1-15; N2a-17; N2b-52; N2c-22; N3-0	66 Gy to the tumor bed was 66 or 60 Gy in 33 or 30 fractions of 2 Gy each over 7 or 6 weeks	Concurrent chemotherapy comprised cisplatin (100 mg/m ² on days 1, 22, and 43 of RT) or rarely paclitaxel (60 mg/m ² weekly with RT) or carboplatin	2-y OS: 90.6%
White (33)	89	NA	NA	NA	NA	≥66 Gy in 25 fractions over 5 weeks	NA	2-y OS: 84.3%; 3-y OS: 82.9%

NA, not available; RT, radiotherapy; cSD, clinical stable disease; cPD, clinical progressive disease; IMRT, intensity modulated radiotherapy; OS, overall survival.

Table 3 Characteristics of the included reduced dose studies

Author	Sample size	Median/mean age of the included patients (years)	Male (%)	T stage	N stage	RT dose	Concurrent therapy	Clinical outcomes
Chen (21)	44	60	NA	T1-16; T2-18; T3-3; T4-7	N0-2; N1-3; N2a-9; N2b-19; N2c-10; N3-1	Definitive radiation given concurrently for 5-6 weeks, chemoradiotherapy was initiated at least 2 weeks following completion of induction chemotherapy	Two cycles of induction chemotherapy with 175 mg/m ² paclitaxel infused over 3 h plus carboplatin as a 30 min infusion, given 21 days apart. This induction regimen was followed by chemoradiotherapy comprising 30 mg/m ² paclitaxel infused over 1 h per week with definitive radiation given concurrently for 5-6 weeks	2-y OS: 98.0%
Marur (22)	51	58	96	T1-11; T2-26; T3-8; T4-6	N0-N1-7; N2a-N2b-29; N2c-15	Cases with cCR on exam/imaging received 54 Gy/27 fx to areas of initial involvement, and the uninvolved cervical nodes (caudal to bilateral clavicles) received 51.3 Gy/27 fx	Patients received IC with cisplatin 75 mg/m ² on day 1; paclitaxel 90 mg/m ² on days 1, 8, and 15; and cetuximab 400 mg/m ² on day 1 of cycle 1, followed by cetuximab 250 mg/m ² weekly; patients continued weekly cetuximab until completion of radiotherapy	2-y OS: 94.0%; 3-y OS: 94.0%
Yom (23)	157	NA	84.7	T1-115; T2-147; T3-44; N0-13; N1-62; N2a-43; N2b-188	N0-6; N1-28; N2a-24; N2b-99	60 Gy of intensity-modulated radiation therapy in 30 fractions, at five fractions per week	Concurrent with cisplatin at 40 mg/m ² weekly	2-y OS: 96.7%; 3-y OS: 95.0%
Misiukiewicz (24)	12	57	NA	T1-T2-7; T3-5; T4-0	N0-0; N1-N2-3; N2c-N3-9	Cases with cPR/cCR on exam/imaging were randomized to 56 Gy/28 fx to involved areas & 50.4 Gy/28 fx to the elective neck	8 of 12 patients received carboplatin only as a radiosensitizer	2-y OS: 87.5%; 3-y OS: 87.5%
Fietkau (25)	NA	NA	NA	NA	NA	The prescribed radiation doses included 63.6 Gy to the gross primary tumor volume (PTV 1 = boost), 58 Gy to involved nodal levels (PTV 2), and 49.6 Gy (PTV 3) to low-risk neck regions	Paclitaxel 20 mg/m ² on days 2, 5, 8, 11, 25, 30, 33, and 36; cisplatin 20 mg/m ² , days 1-4 and 29-32	2-y OS: 92.3%; 3-y OS: 92.3%

Table 3 (continued)

Table 3 (continued)

Author	Sample size	Median/mean age of the included patients (years)	Male (%)	T stage	N stage	RT dose	Concurrent therapy	Clinical outcomes
Moore (26)	79	61	91	T1-36; T2-27; T3-7; T4-9	N0-1; N1-66; N2-12	Received 30 Gy in 1.5-Gy fractions twice daily (separated by at least 6 hours) over 2 weeks to the primary site and dissected and elective nodal volumes	IV weekly docetaxel (15 mg/m ²) was administered on days 1 and 8 of treatment as a radiosensitizer	3-y OS: 86.3%
Chera (27)	44	61	88.6	T0-2; T1-13; T2-22; T3-7	N0-4; N1-10; N2a-2; N2b-21; N2c-7	The total delivered dose was 60 Gy at 2 Gy per fraction for 30 fractions, 5 days a week for 6 weeks to the high-risk regions. A dose of 54 Gy was delivered to anatomic regions at risk of subclinical disease (as indicated)	Cisplatin at a dose of 30 mg/m ² was given intravenously weekly	3-y OS: 95.0%
Echevarria (28)	146	NA	NA	NA	NA	Doses of <69.3 Gy given over a median 33 fractions in a median of 200 cGy per fraction	NA	3-y OS: 86.3%
Huang (29)	61	61	59	T1-T2-47; T3-14	N0-N2a-40; N2b-16; N2c-5; N3-0	60 Gy in 25 fractions over 5 weeks	NA	3-y OS: 73.0%
Gabani (30)	104	58	84.6	T1-30; T2-15; T3-12; T4-14	N0-6; N1-22; N2a-23; N2b-32; N2c-10; N3-4; NA-7	<66 Gy in 25 fractions over 5 weeks	NA	3-y OS: 82.2%
Tam (31)	124	NA	85.5	T1-29; T2-59; T3-25; NA-11	N0-8; N1-26; N2-9; N2a-11; N2b-56; N2c-13; NA-1	50 to <66 Gy in 25 fractions over 5 weeks	NA	3-y OS: 89.9%
Chin (32)	66	56.2	89.4	T1-23; T2-29; T3-8; T4a-5; T4b-1	N0-2; N1-6; N2a-11; N2b-32; N2c-12; N3-3	The total dose to the tumor bed was 66 or 60 Gy in 33 or 30 fractions of 2 Gy each over 7 or 6 weeks	Concurrent chemotherapy comprised scheduled cisplatin (100 mg/m ² on days 1, 22, and 43 of RT) or rarely paclitaxel (60 mg/m ² weekly with RT) or carboplatin	2-y OS: 96.8%
White (33)	103	NA	NA	NA	NA	<66 Gy in 25 fractions over 5 weeks; sdCRT: ≥66 Gy in 25 fractions over 5 weeks	NA	2-y OS: 84.3%; 3-y OS: 82.9%

NA, not available; cPR, clinical partial response; cCR, clinical complete response; IC, induction chemotherapy; RT, radiotherapy; OS, overall survival; sdCRT, standard dose chemoradiation.

Table 4 Adverse events occurred in the reduced dose group

Toxicities	Chen (21) (n=44)	Marur (22) (n=51)	Misiukiewicz (24) (n=12)	Chera (27) (n=44)
Increased ALT level		1		
Anaphylaxis		1		
Anemia	28	1		
Anorexia	11	4		
Anxiety	5			
Arthralgia	4	1		
Aspiration		1		
Increased AST level		0		
Bone pain	2			
Increased cardiac troponin I level		1		
Catheter-related infection		1		
Decreased CD4 lymphocyte count		1		
Chest pain, cardiac		1		
Constipation	17	0		
Cough	16			
Dehydration	10	6		
Dermatitis radiation	36	0		
Device-related infection		1		
Diarrhea	3	5		
Dry mouth	43	0		1
Dysphagia	23	1		17
Dyspnea		2		
Erythema multiforme		0		
Fatigue		4		
Febrile neutropenia		1	1	
Fever	3			
Gastrointestinal disorders		0		
Generalized muscle weakness		1		
Headache	4	1		
Hematologic				5
Hyperkalemia		1		
Hypokalemia	4	4		
Hypomagnesemia	5	2		
Hyponatremia	8	2		
Hypophosphatemia		1		

Table 4 (continued)

Table 4 (continued)

Toxicities	Chen (21) (n=44)	Marur (22) (n=51)	Misiukiewicz (24) (n=12)	Chera (27) (n=44)
Hypotension		2		
Hypoxia		1		
Increased creatinine	4			
Decreased lymphocyte count		6		
Oral mucositis	38	1	1	15
Myalgia		1		
Myocardial infarction		1		
Nausea	19	4		8
Neuralgia		0		
Neutropenia	9			
Decreased neutrophil count		12		
Oral pain		0		
Pain		0		
Pain in extremities		0		
Palmar-plantar erythrodysesthesia		0		
Peripheral motor neuropathy		0		
Peripheral sensory neuropathy	3	0		
Pharyngitis		0		
Pneumonia	2			
Rash, acneiform		28		
Rash, maculopapular		2		
Renal and urinary disorders, other		0		
Sepsis		1		
Skin ulceration		0		
Sore throat		0		
Thromboembolic event		4		
Tinnitus		1		
Tumor pain		0		
Urinary retention			1	
Voice alteration	6			
Vomiting		0		2
Decreased WBC count	40	6		
Wound complications		1		

ALT, alanine transaminase; AST, aspartate transaminase; CD4, cluster of differentiation 4; WBC, white blood cell.




Figure 1 Flowchart of study selection. Of the 13 studies included in this meta-analysis, 9 studies included both RD and SD, and 4 studies just included in RD. SD, standard dose; RD, reduced dose.

199 count reduction (23.5%), dehydration, lymphocyte count
 200 reduction, and leukocyte count reduction (all 11.8%). The
 201 top three adverse reactions reported by Chera *et al.* were
 202 dry mouth (38.6%), oral mucositis (34.1%), and nausea
 203 (18.2%). Compared with the other three studies, Chen *et al.*
 204 reported the most AEs, with 43 people suffering from dry
 205 mouth, 40 people suffering from decreased white blood cell
 206 (WBC) count, and 38 people suffering from oral mucositis.
 207 In summary, the most common complication of RD was
 208 mucositis oral, affecting 36.4% of patients, followed by
 209 decreased WBC count (30.5%) and dry mouth (29.1%).

210

211

Sensitivity analysis and evaluation of publication bias

212

213

214

215

216

217

218

219

Discussion

220

221

222

It is known that patients with HPV-associated OPC have an excellent prognosis. Studies have shown that these

223 patients are more sensitive to radiation therapy (35), and
 224 can achieve the same therapeutic effect by reducing the
 225 radiation dose. Although this topic is at the forefront of
 226 oncologic research, there is currently a lack of summative
 227 assessment. Therefore, we compared the effects of reduced
 228 and standard doses in HPV-related OPC on survival and
 229 the incidence of AEs. Our results suggested that patients
 230 with HPV-related OPC could be treated with a lower dose
 231 compared to standard treatment, and there are fewer AEs
 232 after radiotherapy. This study may lead to a change in the
 233 treatment options for patients with oropharyngeal cancer.

234 In this study, we selected patients who were HPV-
 235 related and divided them into two groups: SD and RD
 236 treatment groups, and observed their survival conditions. As
 237 mentioned above, we observed that patients who received
 238 a RD had superior 2y-OS and 3y-OS rates than those who
 239 received SD treatment (95.66 vs. 91.51; 88.36 vs. 87.46,
 240 respectively). Moreover, the 2- and 3-year PFS rates
 241 were not significantly different between the two groups.
 242 Numerous factors influence the prognosis of OPC, such
 243 as disease stage, gender, smoking state, HPV subtype, etc.
 244 (10,23,24,36). In our research, the disease stage, gender, and
 245 smoking state were not disparate between the two groups,
 246 so we excluded their influence. HPV infection can be




Figure 2 Meta-analysis (forest plot) of the OS reported in RD and SD studies. OS, overall survival; RD, reduced dose; SD, standard dose.




Figure 3 Meta-analysis (forest plot) of the PFS reported in RD and SD studies. PFS, progression-free survival; RD, reduced dose; SD, standard dose.

247 classified into P16+/HPV+, p16+/HPV-, or p16-/HPV+.
 248 Some studies have reported that the OS of p16+/HPV- and
 249 p16-/HPV+ are poor (37). However, the included studies in
 250 this meta-analysis failed to distinguish between these three
 251 specific categories, and thus, we could not determine whether
 252 our results were affected by HPV status in the two groups.
 253 It is hoped that the currently ongoing clinical trials (38)

consider the subtype of HPV states to ascertain whether
 different HPV states affect the prognosis of treatment
 to varying degrees and clarify which HPV has a superior
 effect.

In our retrospective analysis, the main AE of RD
 treatment was oral mucositis, occurring in 36.4% of
 patients. Comparing the four studies that mentioned

261 AEs, Fietkau *et al.* (25), Yom *et al.* (23), and Echevarria
 262 *et al.* (28) reported fewer AEs, which may be related to
 263 the use of the chemotherapy drug, carboplatin. A trial
 264 comparing cetuximab and cisplatin chemoradiotherapy
 265 (CRT) as presented by a European group at European
 266 Society for Medical Oncology (ESMO) 2018 (30), which
 267 confirmed that platinum can enhance radiosensitivity and
 268 reduce AEs. Although the reported incidence of adverse
 269 reactions seemed high in Chen *et al.* (21), they were mainly
 270 concentrated in Grades 1–2, which are relatively mild and
 271 do not significantly impact the quality of life of patients.
 272 Compared with the other three studies, Chen *et al.* employed
 273 combination treatment using paclitaxel and carboplatin
 274 instead of platinum monotherapy; thus, we speculate
 275 that the higher rates of adverse reactions in their study
 276 may be related to the multiple chemotherapy regimen
 277 combinations.

278 Unfortunately, detailed adverse events in the SD group
 279 were not collected in our study, so it was impossible to
 280 compare the two groups. Nevertheless, further analysis
 281 revealed that all of the relevant research results concerning
 282 radiotherapy dose reduction indicated fewer adverse
 283 reactions. Standard chemoradiotherapy regimens are
 284 associated with substantial toxic effects, including in organs
 285 involved in salivation, swallowing, and mucosal integrity,
 286 with dose-related side effects. Probability models utilized
 287 for complications in normal tissue show that with each
 288 1 Gy increase in the mean dose to the parotid gland,
 289 the likelihood of xerostomia increases by about 5% at
 290 1-year post-treatment (39). Likewise, the incidence of
 291 late dysphagia and gastrostomy tube dependence rises
 292 with increasing pharyngeal constrictor, larynges, and
 293 cricopharyngeal inlet doses. Thus, reducing the radiation
 294 dose in selected patients with favorable biology (HPV-
 295 related) has the potential to improve treatment tolerability
 296 while at the same time preserving long-term function.

297 The systematic review conducted in this study showed
 298 that lower doses could reduce post-treatment AEs, either
 299 the incidence of decreased quality of life (40) or late
 300 adverse reactions (25). Some studies (28,41–43) have shown
 301 that, after dose reduction, the symptoms of dry mouth,
 302 hypogeusia, and dysphagia continue to improve, and
 303 gastrostomy tube (PEG) placement rates and late toxicity
 304 were also lower (43–45). It has also been reported (46) that
 305 the target volume of OPC could combine dose reduction
 306 with unilateral irradiation for improving mild to moderate
 307 acute swallowing dysfunction. Taken together, these results

indicate that reducing the radiation dose is conducive to 308
 improving the quality of life of patients and enhancing the 309
 functioning of affected organs. 310

This article had several limitations that should be noted. 311
 Firstly, the sample size of the included trials is small, and 312
 there is a lack of randomized phase III clinical trial results. 313
 Furthermore, due to the inclusion of clinical trials with 314
 potential selection bias, the compared treatment strategies and 315
 follow-up periods are largely different among various studies, 316
 which may have impacted the results. Lastly, the vast majority 317
 of included studies failed to provide long-term follow- 318
 up. HPV-related tumor recurrences continue after 3 years 319
 of therapy (10) and the cumulative incidence of late AEs 320
 consistently increases over a longer period (14), implying that 321
 toxicity reporting is likely understated, and the outcomes 322
 are likely overestimated to some extent. Nevertheless, these 323
 shortcomings do not detract from the promising short-term 324
 results of treatment de-escalation a concept that seeks to 325
 improve the therapeutic ratio for this expanding population. 326
 327

328 Conclusions

329 This systematic review and pooled analysis revealed that 330
 compared to standard radiation doses, radiation dose 331
 reduction in patients with HPV-related OPC provided 332
 superior therapeutic outcomes and optimized quality of life, 333
 but had similar PFS rates. Prospective randomized trials or 334
 studies with large sample sizes are needed to validate these 335
 findings. 336
 337

338 Acknowledgments

339 We thank all the members of the Radiation Oncology 340
 Translational Research Group (ROTRG) who participated 341
 in this study. 342

343 *Funding:* The current study was supported by grants from 344
 the National Natural Science Foundation of China (No. 345
 81802740 to JD Sui; No. 81972857 to Y Wang), the 346
 Chongqing Science and Health Joint Medical Research 347
 Project (No. 2022ZDXM028 to JD Sui), and the Natural 348
 Science Foundation of Chongqing City (No. cstc2021jcsx- 349
 msxm0029 to Y Wang). 350
 351

352 Footnote

353 *Reporting Checklist:* The authors have completed the 354
 MOOSE reporting checklist. Available at <https://atm.> 355

355 amegroups.com/article/view/10.21037/atm-22-5935/rc

356

357 *Conflicts of Interest:* All authors have completed the
 358 ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-5935/coif>).
 359 JDS reports that the current study was supported by grants
 360 from the National Natural Science Foundation of China
 361 (No. 81802740), and the Chongqing Science and Health
 362 Joint Medical Research Project (No. 2022ZDXM028).
 363 YW reports that the current study was supported by grants
 364 from the National Natural Science Foundation of China
 365 (No. 81972857), and the Natural Science Foundation of
 366 Chongqing City (No. cstc2021jscx-msxm0029). The other
 367 authors have no conflicts of interest to declare.
 368

369

370 *Ethical Statement:* The authors are accountable for all
 371 aspects of the work in ensuring that questions related
 372 to the accuracy or integrity of any part of the work are
 373 appropriately investigated and resolved.
 374

375

376 *Open Access Statement:* This is an Open Access article
 377 distributed in accordance with the Creative Commons
 378 Attribution-NonCommercial-NoDerivs 4.0 International
 379 License (CC BY-NC-ND 4.0), which permits the non-
 380 commercial replication and distribution of the article with
 381 the strict proviso that no changes or edits are made and the
 382 original work is properly cited (including links to both the
 383 formal publication through the relevant DOI and the license).
 384 See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

385

References

386

387

388 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics
 389 2020: GLOBOCAN Estimates of Incidence and Mortality
 390 Worldwide for 36 Cancers in 185 Countries. *CA Cancer J*
 391 *Clin* 2021;71:209-49.
 392 2. Bernier J, Dommene C, Ozsahin M, et al. Postoperative
 393 irradiation with or without concomitant chemotherapy
 394 for locally advanced head and neck cancer. *N Engl J Med*
 395 2004;350:1945-52.
 396 3. Du J, Nordfors C, Ahrlund-Richter A, et al. Prevalence
 397 of oral human papillomavirus infection among youth,
 398 Sweden. *Emerg Infect Dis* 2012;18:1468-71.
 399 4. Guo T, Eisele DW, Fakhry C. The potential impact
 400 of prophylactic human papillomavirus vaccination on
 401 oropharyngeal cancer. *Cancer* 2016;122:2313-23.
 402 5. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human
 papillomavirus and rising oropharyngeal cancer incidence

in the United States. *J Clin Oncol* 2011;29:4294-301. 403

6. Gillison ML, Chaturvedi AK, Anderson WF, et al. 404
 Epidemiology of Human Papillomavirus-Positive Head 405
 and Neck Squamous Cell Carcinoma. *J Clin Oncol* 406
 2015;33:3235-42. 407
7. Senkomago V, Henley SJ, Thomas CC, et al. Human 408
 Papillomavirus-Attributable Cancers - United States, 2012- 409
 2016. *MMWR Morb Mortal Wkly Rep* 2019;68:724-8. 410
8. Schache AG, Powell NG, Cuschieri KS, et al. HPV- 411
 Related Oropharynx Cancer in the United Kingdom: 412
 An Evolution in the Understanding of Disease Etiology. 413
Cancer Res 2016;76:6598-606. 414
9. Craig SG, Anderson LA, Schache AG, et al. 415
 Recommendations for determining HPV status in patients 416
 with oropharyngeal cancers under TNM8 guidelines: a 417
 two-tier approach. *Br J Cancer* 2019;120:827-33. 418
10. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus 419
 and survival of patients with oropharyngeal cancer. *N Engl 420
 J Med* 2010;363:24-35. 421
11. Rieckmann T, Tribius S, Grob TJ, et al. HNSCC cell 422
 lines positive for HPV and p16 possess higher cellular 423
 radiosensitivity due to an impaired DSB repair capacity. 424
Radiother Oncol 2013;107:242-6. 425
12. Gillison ML, D'Souza G, Westra W, et al. Distinct risk 426
 factor profiles for human papillomavirus type 16-positive 427
 and human papillomavirus type 16-negative head and neck 428
 cancers. *J Natl Cancer Inst* 2008;100:407-20. 429
13. Tsai CJ, McBride SM, Riaz N, et al. Evaluation of 430
 Substantial Reduction in Elective Radiotherapy Dose and 431
 Field in Patients With Human Papillomavirus-Associated 432
 Oropharyngeal Carcinoma Treated With Definitive 433
 Chemoradiotherapy. *JAMA Oncol* 2022;8:364-72. 434
14. Machtay M, Moughan J, Trotti A, et al. Factors associated 435
 with severe late toxicity after concurrent chemoradiation 436
 for locally advanced head and neck cancer: an RTOG 437
 analysis. *J Clin Oncol* 2008;26:3582-9. 438
15. Owadally W, Hurt C, Timmins H, et al. PATHOS: a phase 439
 II/III trial of risk-stratified, reduced intensity adjuvant 440
 treatment in patients undergoing transoral surgery for 441
 Human papillomavirus (HPV) positive oropharyngeal 442
 cancer. *BMC Cancer* 2015;15:602. 443
16. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus 444
 cetuximab or cisplatin in human papillomavirus-positive 445
 oropharyngeal cancer (NRG Oncology RTOG 1016): 446
 a randomised, multicentre, non-inferiority trial. *Lancet* 447
 2019;393:40-50. 448
17. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy 449
 plus cisplatin or cetuximab in low-risk human 450

- 451 papillomavirus-positive oropharyngeal cancer (De-
 452 ESCALaTE HPV): an open-label randomised controlled
 453 phase 3 trial. *Lancet* 2019;393:51-60.
- 454 18. Chera BS, Amdur RJ, Green R, et al. Phase II Trial
 455 of De-Intensified Chemoradiotherapy for Human
 456 Papillomavirus-Associated Oropharyngeal Squamous Cell
 457 Carcinoma. *J Clin Oncol* 2019;37:2661-9.
- 458 19. Seiwert TY, Foster CC, Blair EA, et al. OPTIMA: a
 459 phase II dose and volume de-escalation trial for human
 460 papillomavirus-positive oropharyngeal cancer. *Ann Oncol*
 461 2019;30:297-302.
- 462 20. Petrelli F, Luciani A, Ghidini A, et al. Treatment de-
 463 escalation for HPV+ oropharyngeal cancer: A systematic
 464 review and meta-analysis. *Head Neck* 2022;44:1255-66.
- 465 21. Chen AM, Felix C, Wang PC, et al. Reduced-dose
 466 radiotherapy for human papillomavirus-associated
 467 squamous-cell carcinoma of the oropharynx: a single-arm,
 468 phase 2 study. *Lancet Oncol* 2017;18:803-11.
- 469 22. Marur S, Li S, Cmelak AJ, et al. E1308: Phase II Trial of
 470 Induction Chemotherapy Followed by Reduced-Dose
 471 Radiation and Weekly Cetuximab in Patients With HPV-
 472 Associated Resectable Squamous Cell Carcinoma of the
 473 Oropharynx- ECOG-ACRIN Cancer Research Group. *J*
 474 *Clin Oncol* 2017;35:490-7.
- 475 23. Yom SS, Torres-Saavedra P, Caudell JJ, et al. Reduced-
 476 Dose Radiation Therapy for HPV-Associated
 477 Oropharyngeal Carcinoma (NRG Oncology HN002). *J*
 478 *Clin Oncol* 2021;39:956-65.
- 479 24. Misiukiewicz K, Gupta V, Miles BA, et al. Standard of
 480 care vs reduced-dose chemoradiation after induction
 481 chemotherapy in HPV+ oropharyngeal carcinoma patients:
 482 The Quarterback trial. *Oral Oncol* 2019;95:170-7.
- 483 25. Fietkau R, Hecht M, Hofner B, et al. Randomized
 484 phase-III-trial of concurrent chemoradiation for locally
 485 advanced head and neck cancer comparing dose reduced
 486 radiotherapy with paclitaxel/cisplatin to standard
 487 radiotherapy with fluorouracil/cisplatin: The PacCis-trial.
 488 *Radiother Oncol* 2020;144:209-17.
- 489 26. Moore EJ, Van Abel KM, Routman DM, et al. Human
 490 papillomavirus oropharynx carcinoma: Aggressive de-
 491 escalation of adjuvant therapy. *Head Neck* 2021;43:229-37.
- 492 27. Chera BS, Amdur RJ, Tepper JE, et al. Mature results of a
 493 prospective study of deintensified chemoradiotherapy for
 494 low-risk human papillomavirus-associated oropharyngeal
 495 squamous cell carcinoma. *Cancer* 2018;124:2347-54.
- 496 28. Echevarria M, Yang GQ, Naghavi AO, et al. Effectiveness
 497 of Dose De-escalation of Primary and/or Elective Neck
 498 in HPV positive Oropharyngeal Cancers. *International*
Journal of Radiation Oncology Biology Physics 2019;105:E416. 499
29. Huang SH, O'Sullivan B, Su J, et al. Hypofractionated
 radiotherapy alone with 2.4 Gy per fraction for head
 and neck cancer during the COVID-19 pandemic: The
 Princess Margaret experience and proposal. *Cancer*
 2020;126:3426-37. 500
30. Gabani P, Lin AJ, Barnes J, et al. OA02 - Dose De-
 Escalated Radiation Therapy versus Standard
 Dose Radiation Therapy in Definitive Treatment
 of HPV-Positive Oropharyngeal Squamous Cell
 Carcinoma. *International Journal of Radiation*
*Oncology*Biolog y*Physics* 2019;103:E1. 501
31. Tam M, Wu SP, Gerber NK, et al. Radiotherapy dose
 and survival outcomes in human papillomavirus positive
 oropharyngeal cancer. *Journal of Laryngology and*
Otology 2020;134:533-40. 502
32. Chin RL, Spencer CR, DeWees T, et al. Reevaluation of
 postoperative radiation dose in the management of human
 papillomavirus-positive oropharyngeal cancer. *Head and*
Neck-Journal for the Sciences and Specialties of the Head
and Neck 2016;38:1643-9. 503
33. White R, Abel S, Hasan S, et al. Practice patterns and
 outcomes following radiation dose de-escalation for
 oropharyngeal cancer. *Laryngoscope* 2020;130:E171-E6. 504
34. Patel RR, Ludmir EB, Augustyn A, et al. De-
 intensification of therapy in human papillomavirus
 associated oropharyngeal cancer: A systematic review of
 prospective trials. *Oral Oncol* 2020;103:104608. 505
35. Lechner M, Liu J, Masterson L, et al. HPV-associated
 oropharyngeal cancer: epidemiology, molecular
 biology and clinical management. *Nat Rev Clin Oncol*
 2022;19:306-27. 506
36. O'Sullivan B, Huang SH, Siu LL, et al. Deintensification
 candidate subgroups in human papillomavirus-related
 oropharyngeal cancer according to minimal risk of distant
 metastasis. *J Clin Oncol* 2013;31:543-50. 507
37. Garset-Zamani M, Carlander AF, Jakobsen KK, et
 al. Impact of specific high-risk human papillomavirus
 genotypes on survival in oropharyngeal cancer. *Int J*
Cancer 2022;150:1174-83. 508
38. Ferris RL, Flamand Y, Weinstein GS, et al. Transoral
 robotic surgical resection followed by randomization to
 low-or standard-dose IMRT in resectable p16+ locally
 advanced oropharynx cancer: a trial of the ECOGACRIN
 Cancer Research Group (E3311). *J Clin Oncol* 2020;38. 509
39. Deasy JO, Moiseenko V, Marks L, et al. Radiotherapy
 dose-volume effects on salivary gland function. *Int J Radiat* 510

- 547 Oncol Biol Phys 2010;76:S58-63.
- 548 40. Posner M, Misiukiewicz DK, Hwang M, et al. Survival and
549 Quality of Life Analysis in a Randomized Deintensification
550 Trial for Locally Advanced HPV Positive Oropharynx
551 Cancer Patients. International Journal of Radiation
552 Oncology Biology Physics 2020;106:1146.
- 553 41. Judy GD, Green R, Aumer SL, et al. Preservation of
554 swallowing function with de-intensified chemoradiation
555 therapy for HPV-associated oropharyngeal squamous cell
556 carcinoma. Adv Radiat Oncol 2018;3:356-65.
- 557 42. Pearlstein KA, Wang K, Amdur RJ, et al. Quality
558 of Life for Patients With Favorable-Risk HPV-
559 Associated Oropharyngeal Cancer After De-intensified
560 Chemoradiotherapy. Int J Radiat Oncol Biol Phys
561 2019;103:646-53.
- 562 43. Hegde JV, Shaverdian N, Felix C, et al. Functional
563 Outcomes After De-escalated Chemoradiation Therapy
564 for Human Papillomavirus-Positive Oropharyngeal
Cancer: Secondary Analysis of a Phase 2 Trial. Int J Radiat
Oncol Biol Phys 2018;100:647-51.
- 565
566
- 567 44. Yang GQ, Gintz D, Naghavi AO, et al. De-escalation of
568 primary target and elective neck doses in HPV-positive
569 oropharyngeal cancers. International Journal of Radiation
570 Oncology Biology Physics 2018;100:1326-7.
- 571
572
- 573 45. Kennedy J, Gintz D, Shah K, et al. Small Reductions
574 in Dose Appear Equally Effective for HPV Positive
575 Oropharyngeal Cancer Patients. International Journal of
576 Radiation Oncology Biology Physics 2017;98:E28-E9.
- 577
578
- 579 46. Yan SX, Mojica J, Barbee D, et al. De-escalation in HPV
580 Era: Definitive Unilateral Neck Radiation for T3 or
581 N2b/N3 p16+ Tonsil Squamous Cell Carcinoma Using
Prospectively Defined Criteria. International Journal of
Radiation Oncology Biology Physics 2019;105:E431.
- (English Language Editor: A. Kaseem)

Cite this article as: Yang MQ, Liu YC, Sui JD, Jin F, Li D, Zhang L, Wang NH, Xie Y, Wang Y, Wu YZ. Reduced-dose radiation in human papillomavirus-associated oropharyngeal carcinoma can improve outcome: a systematic review and meta-analysis. *Ann Transl Med* 2022;10(24):1391. doi: 10.21037/atm-22-5935